Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2341-2351

  Rossi, Edmund A ^a,b   Rossi, Diane L ^a   Cardillo, Thomas M ^a   Chang, Chien Hsing ^a,b   Goldenberg, David M ^a,b,c  

^a IMMUNOMEDICS INC   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC ANTIBODY (E1) 3S; CD3 ANTIGEN; CD69 ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN; TROP 2 PROTEIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; CELL ADHESION MOLECULE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL KILLING; CELL PROLIFERATION; CELLULAR PARAMETERS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; EX VIVO STUDY; FEMALE; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; IC50; IMMUNOLOGICAL SYNAPSE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NCI 287 CELL LINE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STOMACH CANCER; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TROGOCYTOSIS; TUMOR XENOGRAFT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; IMMUNOLOGY; NEOPLASMS; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; MICE, INBRED NOD; MICE, SCID; NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84920826956     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0345     Document Type: Article

References (50)

1. Muller D, Kontermann RE. Recombinant bispecific antibodies for cellular cancer immunotherapy. Curr Opin Mol Ther 2007;9:319-26.
2. Kipriyanov SM, Moldenhauer G, Strauss G, Little M. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 1998;77:763-72.
3. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. Arecombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-103.
4. Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, et al. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 2006;12:4036-42.
5. Buhler P, Wolf P, Gierschner D, Schaber I, Katzenwadel A, Schultze-Seemann W, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 2008;57:43-52.
6. Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, et al. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate 2011;71:998-1011.
7. Fortmuller K, Alt K, Gierschner D, Wolf P, BaumV, Freudenberg N, et al. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA x CD3 bispecific single-chain diabody. Prostate 2011;71:588-96.
8. Muller D, Kontermann RE. Bispecifi c antibodies for cancer immunotherapy: current perspectives. BioDrugs 2010;24:89-98.
9. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009;69:4941-4.
10. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T-cell-engaging antibody. Science 2008;321:974-7.
11. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8.
12. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, Schlereth B, et al. Mode of cytotoxic action of T-cell-engaging BiTE antibody MT110. Immunobiology 2009;214:441-53.
13. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008;99:1290-5.
14. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, van HT, Ashfaq R, Meyer R, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 2002;160:1239-49.
15. Kapoor S. TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors. Tumour Biol 2013;34:1967-8.
16. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009;62:152-8.
17. Stein R, Basu A, Chen S, Shih LB, Goldenberg DM. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer 1993;55:938-46.
18. Rossi DL, Rossi EA, Cardillo TM, Goldenberg DM, Chang CH. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. MAbs 2013;6:381-91.
19. Rossi EA, Goldenberg DM, Chang CH. The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2012;23:309-23.
20. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 2002;29:18-26.
21. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17:117-27.
22. Grimley PM, Fang H, Rui H, Petricoin EF III, Ray S, Dong F, et al. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-alpha. Blood 1998;91:3017-27.
23. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le BA, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011;17:2619-27.
24. Agarwal P, Raghavan A, Nandiwada SL, Curtsinger JM, Bohjanen PR, Mueller DL, et al. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol 2009;183:1695-704.
25. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005;174:4465-9.
26. Hervas-Stubbs S, Riezu-Boj JI, Gonzalez I, Mancheno U, Dubrot J, Azpilicueta A, et al. Effects of IFN-alpha as a signal-3 cytokine on human naive and antigen-experienced CD8(+) T cells. Eur J Immunol 2010;40:3389-402.
27. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005;202:637-50.
28. Le BA, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, et al. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol 2006;176:4682-9.
29. Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 2014;63:259-71.
30. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999;189:521-30.
31. Thompson LJ, Kolumam GA, Thomas S, Murali-Krishna K. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immunol 2006;177:1746-54.
32. Ahmed KA, Munegowda MA, Xie Y, Xiang J. Intercellular trogocytosis plays an important role in modulation of immune responses. Cell Mol Immunol 2008;5:261-9.
33. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol 2003;4:815.
34. Sharkey RM, van Rij CM, Karacay H, Rossi EA, Frielink C, Regino C, et al. A new Tri-Fab bispeci fic antibody for pretargeting Trop-2-expressing epithelial cancers. J Nucl Med 2012;53:1625-32.
35. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003;170:4397-402.
36. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009;114:3864-71.
37. Rossi EA, Chang CH, Cardillo TM, Goldenberg DM. Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. Bioconjug Chem 2013;24:63-71.
38. Brandl C, Haas C, d'Argouges S, Fisch T, Kufer P, Brischwein K, et al. The effect of dexamethasone on polyclonal T-cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 2007;56:1551-63.
39. Flieger D, Kufer P, Beier I, Sauerbruch T, Schmidt-Wolf IG. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural killer-like T lymphocytes to EpCAM-expressing tumor cells. Cancer Immunol Immunother 2000;49:441-8.
40. Kroesen BJ, Nieken J, Sleijfer DT, Molema G, de Vries EG, Groen HJ, et al. Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol Immunother 1997;45:203-6.
41. Panelli MC, White R, Foster M, Martin B, Wang E, Smith K, et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004;2:17.
42. Eastwood D, Bird C, Dilger P, Hockley J, Findlay L, Poole S, et al. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol 2013;76:299-315.
43. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119:6226-33.
44. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712.
45. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-91.
46. Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008;7:280-5.
47. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression pro files in normal and cancer cells. Science 1997;276:1268-72.
48. Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 2013;32:222-33.
49. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011;17:3157-69.
50. Starodub AE, Ocean AJ, Shah MA, Vahdat LT, Chuang E, Guarino MJ, et al. SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA: AACR; 2014. Abstract nr CT206.